TrialHaematologica2016

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.

Stefano Sacchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.